Research & Development
Immune Tolerance Platform

Induced Treg
Cell Therapy

Transforming organ transplantation from lifelong immunosuppression to durable, cell-mediated immune tolerance.

FOXP3 IL-10 TGF-β IL-35 Teff Teff Teff Teff iTreg-MEDIATED IMMUNE TOLERANCE
Our Vision

From Lifelong Suppression to Durable Tolerance

Regulatory T cells (Tregs) are the immune system's natural peacekeepers — CD4+ cells defined by FOXP3 that selectively suppress harmful responses while preserving protective immunity. Half of all kidney transplants fail within 10–15 years. Calcineurin inhibitors — the standard of care — paradoxically damage the organ they protect, while increasing infection and cancer risk 2–4×. Wondercel's iTreg platform was engineered to break this cycle through scalable manufacturing of stable, potent FOXP3+ iTregs for repeated clinical dosing.

Early clinical signal: In 2 kidney transplant recipients treated with Wondercel's induced Treg platform, immunosuppression was successfully reduced to low-dose monotherapy — with the next milestone being complete immunosuppression withdrawal while maintaining stable graft function.
TODAY Lifelong daily regimen ✕ Organ toxicity (CNI) ✕ 2–4× cancer risk ✕ Chronic infections ✕ Graft failure 10–15Y Broad suppression TOMORROW iTreg FOXP3⁺ Repeat-dose infusions ✓ Selective tolerance ✓ Reduced drug burden ✓ No organ toxicity ✓ Extended graft survival Targeted tolerance
Wondercel iTreg Platform

Scalable Autologous iTreg Manufacturing

A proprietary ex-vivo induction platform that converts conventional T cells into stable, potent FOXP3+ iTregs at clinical scale.

01

Blood Collection

Peripheral blood mononuclear cells collected from the transplant recipient

→
02

Ex-Vivo Induction

Proprietary cytokine and signaling cocktail drives stable FOXP3+ differentiation

→
03

GMP Expansion

Large-scale manufacturing with comprehensive phenotype and functional quality control

→
04

Repeated Infusion

Multiple doses to build and maintain durable transplant tolerance

Clinical Advantages

Beyond What Drugs Can Achieve

iTreg therapy addresses the fundamental limitations of broad immunosuppression with four distinct mechanisms of action.

Dual Rejection Control

Tregs suppress both T-cell-mediated and antibody-mediated rejection through CTLA-4 competition, inhibitory cytokines, and follicular Treg regulation of B-cell responses.

Drug Reduction or Withdrawal

By inducing antigen-specific tolerance, iTreg therapy enables progressive reduction or elimination of immunosuppressants — alleviating organ toxicity and metabolic complications.

Extended Graft Survival

Tregs modulate the graft microenvironment — promoting tissue repair, suppressing chronic inflammation and fibrosis, potentially extending graft longevity beyond current benchmarks.

Scalable & Repeatable

Clinically relevant iTreg doses produced at scale, supporting multiple infusions per patient — essential for building and sustaining long-term immune tolerance.

A New Chapter in Transplant Medicine

Making immune tolerance — not immunosuppression — the standard of care for organ transplant recipients worldwide.

~160K Organ transplants
per year globally
10–15 Y Median graft
half-life today
2–4× Elevated cancer risk
on immunosuppressants
  • North Area, Building E, Floors 3-4, Qianhai Shenzhen-Hong Kong Youth Innovation Hub, Nanshan District, Shenzhen, Guangdong Province, China
  • 0755-86971801

微信公众号

Copyright © 2024 Wondercel Therapeutics Powered by vancheer